However, SHP099 does not reduce the viability of B16F10 cells even when the cells are cultured in 2–20% Matrigel, under conditions that have revealed increased sensitivity to SHP099 in certain KRAS‐mutant cancer cells (Hao et al,2019) (Fig EV2E). This evidence concerns the gene KRAS and cancer.